How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastasis-from-malignant-tumor-of-prostate.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastasis from malignant tumor of prostate — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastasis from malignant tumor of prostate (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastasis from malignant tumor of prostate, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Erleada	apalutamide	Johnson & Johnson		Androgen receptor	2018-01-01
Xtandi	enzalutamide	Astellas Pharma	Androgen Receptor Inhibitor [EPC]	Androgen receptor	2012-01-01
Xtandi	xtandi	Astellas Pharma	Androgen receptor inhibitor	Androgen receptor	2012-01-01
MDV3100	mdv3100	Pfizer Inc.	Androgen receptor inhibitor	Androgen receptor, Glucocorticoid receptor, Prostate-specific antigen

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Astellas Pharma · 2 drugs in Metastasis from malignant tumor of prostate
Johnson & Johnson · 1 drug in Metastasis from malignant tumor of prostate
Pfizer Inc. · 1 drug in Metastasis from malignant tumor of prostate

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastasis from malignant tumor of prostate:

Cite this brief

Drug Landscape (2026). Metastasis from malignant tumor of prostate — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastasis-from-malignant-tumor-of-prostate. Accessed 2026-06-10.

Metastasis from malignant tumor of prostate full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing